INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Rhea-AI Summary

INVO Fertility (Nasdaq: IVF) will participate in H.C. Wainwright's 28th Annual Global Investment Conference, held September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded virtual company presentation will be available on demand starting September 11, 2026, at 7:00 a.m. ET via the H.C. Wainwright conference portal.

According to INVO Fertility, management will also be available for one-on-one investor meetings during the conference. A slide presentation is accessible on the company’s investor relations website, and investors can schedule meetings through H.C. Wainwright or INVO’s investor relations contacts.

Market Context

The -0.88% reaction to the Aug 20, 2026 research announcement places this conference notice within a...

Analysis

The -0.88% reaction to the Aug 20, 2026 research announcement places this conference notice within a mixed news-response record. The platform also records moderate short positioning, a risk factor to monitor alongside future disclosures.

Key Figures

Conference Edition: 28th annual Presentation Availability: September 11, 2026, at 7:00 a.m. ET Conference Dates: September 14-16, 2026 +1 more

4 metrics

Conference Edition 28th annual H.C. Wainwright Global Investment Conference

Presentation Availability September 11, 2026, at 7:00 a.m. ET Pre-recorded virtual presentation

Conference Dates September 14-16, 2026 H.C. Wainwright Global Investment Conference

Operational Clinics four clinics United States

Historical Context

5 past events · Latest: Aug 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 20	Research presentations	Positive	-0.9%	Five retrospective PRP studies presented at a reproductive medicine symposium.
Aug 17	Second-quarter earnings	Positive	+57.5%	Revenue growth and clinic-level profitability accompanied the quarterly results.
Jun 22	First-quarter earnings	Negative	-7.3%	Revenue growth and capital-structure improvements were offset by a continuing-operations net loss.
Jun 02	Nasdaq compliance notice	Negative	+11.8%	Nasdaq issued a delinquency notice concerning delayed annual and quarterly filings.
Jun 02	Fiscal-year earnings	Negative	+3.4%	Revenue increased, but the company reported continuing losses and weaker adjusted EBITDA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions were mixed, with two events aligned with their apparent news direction and three showing divergence.

Key Terms

assisted reproductive technology, in vitro fertilization, intravaginal culture, in vivo

4 terms

assisted reproductive technology medical

"expanding access to assisted reproductive technology ("ART") care"

Assisted reproductive technology (ART) is a set of medical procedures used to help people conceive when natural conception is difficult or impossible, including techniques such as in vitro fertilization (IVF), intracytoplasmic sperm injection, egg or sperm donation, embryo transfer and related laboratory and drug treatments. Think of it as a high-tech toolkit that replaces or assists parts of the natural fertilization process; it matters to investors because ART services and products are driven by patient demand, regulatory rules, reimbursement policies and technological advances, all of which affect clinic volumes, device and drug sales, and long-term revenue potential.

in vitro fertilization medical

"fertility services including in vitro fertilization ("IVF")"

In vitro fertilization (IVF) is a medical procedure that fertilizes an egg with sperm outside the body in a laboratory dish, then transfers the resulting embryo to a uterus to achieve pregnancy. Investors care because IVF drives demand for specialized clinics, medical devices, drugs, and insurance coverage—similar to how a new product line creates sales and service needs—so changes in treatment success rates, regulation, or patient demand can affect revenues and costs across healthcare and biotech companies.

intravaginal culture medical

"and the intravaginal culture ("IVC") procedure"

A fertility technique in which eggs and sperm are placed together inside a small, sealed device that is inserted into the woman’s vagina so fertilization and initial embryo development occur using body heat instead of a full laboratory incubator. For investors, it matters because it can lower clinic costs, broaden access to assisted reproduction, and shift demand toward smaller medical devices and different regulatory and reimbursement pathways—similar to moving part of a factory process back into the customer's hands.

in vivo medical

"to take place in vivo within the woman's body"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City.

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET. A copy of the slide presentation is available on the investor relations portion of the INVO Fertility website at https://invofertility.com/investors/events-presentations/.

Members of INVO Fertility's management team will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting should contact their H.C. Wainwright representative at meetings@hcwco.com, or INVO’s investor relations at INVO@lythampartners.com.

Event Details

Conference: 28th Annual H.C. Wainwright Global Investment Conference
Conference Dates: September 14-16, 2026
Pre-Recorded Virtual Presentation: Available beginning Friday, September 11, 2026, at 7:00 a.m. ET
Presentation Access: H.C. Wainwright conference portal

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology ("ART") care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization ("IVF") and the intravaginal culture ("IVC") procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. For more information, please visit invofertility.com.

For more information, please contact:

INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com

Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com

FAQ

When will INVO Fertility's (Nasdaq: IVF) virtual presentation be available for the H.C. Wainwright 2026 conference?

INVO Fertility’s virtual presentation will be available on demand starting September 11, 2026, at 7:00 a.m. ET. According to INVO Fertility, access will be provided through the H.C. Wainwright conference portal as part of the 28th Annual Global Investment Conference.

What are the dates and location of the H.C. Wainwright 28th Annual Global Investment Conference featuring INVO Fertility (IVF)?

The conference runs from September 14 to 16, 2026, at the Lotte New York Palace Hotel in New York City. According to INVO Fertility, the company will participate and offer a pre-recorded presentation plus one-on-one investor meeting availability.

How can investors schedule one-on-one meetings with INVO Fertility (IVF) during the September 2026 H.C. Wainwright conference?

Investors can schedule meetings by contacting their H.C. Wainwright representative or emailing INVO’s investor relations at INVO@lythampartners.com. According to INVO Fertility, management will be available for one-on-one investor meetings throughout the conference dates.

Where can investors access INVO Fertility's slide presentation related to the H.C. Wainwright 2026 conference?

The slide presentation is available on the investor relations section of the INVO Fertility website. According to INVO Fertility, investors can visit invofertility.com/investors/events-presentations/ to review the materials supporting the company’s participation in the Global Investment Conference.

What services and clinics does INVO Fertility (Nasdaq: IVF) operate as of August 2026?

INVO Fertility focuses on building, acquiring, and operating fertility clinics and related technologies, with four operational U.S. clinics. According to INVO Fertility, its clinics provide IVF and intravaginal culture (IVC) using the proprietary INVOcell device, and it distributes INVOcell to third-party clinics.